SCHEMBL206355

SCHEMBL206355

CN(C)c1ccc(-c2csc(Nc3ccc(OC4CCCC4)c(C(F)(F)F)c3)n2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 1/20 0.44
ALOX5 P09917 3/20 0.40
CDK2 P24941 1/20 0.39
KDR P35968 1/20 0.39
RORC P51449 1/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP1B1 Q16678 1/20 0.38
MAPT P10636 6/20 0.38
MAPK1 P28482 3/20 0.38
GAA P10253 2/20 0.38
RAB9A P51151 2/20 0.38
CDK1 P06493 1/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
VCP P55072 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205482 0.89 P2RX3 (0.46) P2RX3ALOX5CDK2KDRRORC
SCHEMBL209144 0.87 P2RX3 (0.44) P2RX3ALOX5CDK2KDRRORC
SCHEMBL205538 0.85 VCP (0.43) P2RX3ALOX5CDK1VCP
SCHEMBL206165 0.84 ALOX5 (0.49) P2RX3ALOX5CYP1A1CYP1A2CYP1B1
SCHEMBL205822 0.83 PTGS2 (0.56) P2RX3ALOX5CYP1A1CYP1A2CYP1B1
SCHEMBL205592 0.83 P2RX3 (0.42) P2RX3ALOX5RORCMAPTRAB9A
SCHEMBL206223 0.82 MEN1 (0.53) CYP1A1CYP1A2CYP1B1MAPTMAPK1
SCHEMBL207320 0.82 P2RX3 (0.46) P2RX3ALOX5CYP1A1CYP1A2CYP1B1
SCHEMBL208075 0.81 S1PR1 (0.44) ALOX5CYP1A1CYP1A2CYP1B1MAPT
SCHEMBL207853 0.80 CDK1 (0.42) P2RX3CDK2KDRRORCMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 P2RX3 2027/4885ALOX5 3410/4885CDK2 740/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 P2RX3 2027/4885ALOX5 3410/4885CDK2 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.